Welcome to our dedicated page for Emmaus Life Scie news (Ticker: EMMA), a resource for investors and traders seeking the latest updates and insights on Emmaus Life Scie stock.
Emmaus Life Sciences, Inc. (OTCQB: EMMA) is a commercial-stage biopharmaceutical company that describes itself as a leader in the treatment of sickle cell disease. Its news flow centers on Endari®, a prescription-grade L-glutamine oral powder indicated to reduce the acute complications of sickle cell disease in adults and children five years of age and older. Emmaus’ press releases provide regular updates on Endari’s regulatory status, geographic reach, and commercial performance.
On this page, readers can follow EMMA news related to quarterly and annual financial results, where the company reports net revenues from Endari sales, operating expenses, income or loss from operations, and liquidity. These updates often discuss factors such as inventory availability, competition from generic L-glutamine oral powder, and changes in operating cost structures, giving context to the company’s financial trajectory.
Emmaus also issues news about regulatory milestones, such as FDA approval of label enhancements for Endari based on post-marketing pharmacokinetic data. The company has highlighted label changes that clarify dosing by body weight, confirm no unwanted accumulation with twice-daily dosing, and allow administration with or without food. In addition, announcements have covered developments in international markets, including market exclusivity for Endari in the Kingdom of Saudi Arabia and the product’s availability on a named patient or early access basis in several countries.
Corporate and capital structure events appear in Emmaus news as well, including Exchange Agreements for outstanding notes and changes in leadership roles. Investors and observers can use this EMMA news feed to review how Emmaus communicates its strategy around Endari, responds to competitive dynamics, and manages licensing and distribution arrangements. For ongoing insight into the company’s sickle cell disease franchise and related corporate actions, this page aggregates Emmaus Life Sciences’ latest press releases and disclosures.
Emmaus Life Sciences (OTC: EMMA) reported a 2% increase in net revenues to $23.2 million for 2020, despite challenges from the COVID-19 pandemic. The company's operating expenses dropped by $5.2 million to $21 million, resulting in an operating loss of just $32,000 compared to $4.5 million in 2019. Net income improved dramatically to $1.1 million from a net loss of $54.8 million. Emmaus is optimistic about future growth with its product Endari® and ongoing trials.
Emmaus Life Sciences (OTC: EMMA) announced it will delay filing its 2020 Annual Report on Form 10-K, initially due on April 15, 2021. The Audit Committee is scheduled to meet the week of April 19 to review the report and approve its filing. The additional time is needed to complete the audit process. Emmaus plans to release its 2020 operating results shortly after the meeting. CEO Dr. Yutaka Niihara expressed confidence in the audit process and appreciation for shareholders' patience.
Emmaus Life Sciences (OTC: EMMA) has entered a collaboration with Kainos Medicine to spearhead the preclinical development of Kainos' IRAK4 inhibitor (KM10544) as an anti-cancer treatment. The partnership includes a $500,000 cash payment and an equivalent in Emmaus common stock, granting Emmaus rights for potential exclusive licensing of resulting intellectual property. This inhibitor targets malignancies with MYD88 mutations, indicating significant medical and commercial potential. Emmaus has previously reported net revenues of $22.8 million in 2019.
Emmaus Life Sciences (OTC: EMMA) announced on October 14, 2020, that it has sold its remaining shares in Telcon RF Pharmaceutical Inc. for KRW 42 billion (approximately $36.6 million). Following the sale, Emmaus will lend KRW 30 billion (approximately $26.1 million) to Telcon via a convertible bond, which will replace the sold shares as collateral. This transaction aims to eliminate the volatility from Telcon shares and may facilitate a potential up-listing to NASDAQ or NYSE American. Proceeds will be used for working capital.